Transpire Bio announced that it has acquired an exclusive license to develop Suzhou Intragrand Pharma’s ITG-1052, a PDE4 inhibitor, as an inhaled therapeutic for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases. The terms of the deal, which gives Transpire Bio development, manufacturing, and commercialization rights to ITG-1052 outside of China, were not disclosed.
The company’s web site currently shows 4 inhaled products in its pipeline, TRSB001-TRSB004. In 2022, Transpire announced a deal with Recipharm for development of those formulations.
Transpire Bio CEO Xian-Ming Zeng commented, “Utilizing business development, we are able to augment and complement our robust pipeline of inhaled therapeutics. Through this agreement, we aim to utilize our vast expertise in developing inhaled therapeutics to progress ITG-1052 as a best-in-class inhaled treatment for idiopathic pulmonary fibrosis and other indications.”
Suzhou Intragrand Pharma CEO Joseph Zhu said, “We are pleased to announce the in-license of lenamilast (ITG-1052), our PDE4 inhibitor for respiratory diseases, by Transpire Bio, a company with unparalleled leadership and expertise in the development and commercialization of inhaled therapeutics.”
Read the Transpire Bio press release
